ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,827.04
-1.54%
US Tech 100
20,023.60
-1.30%
Dow Jones
41,938.45
-1.63%
Brent Oil
80.415
-0.25%
Bitcoin
92,793.30
-1.80%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Senti Biosciences Inc (SNTI)

  7. Senti Biosciences Inc (SNTI) News

SNTI

Senti Biosciences (SNTI)

Senti Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNTI
DateTimeSourceHeadlineSymbolCompany
01/06/20259:00AMGlobeNewswire Inc.Senti Bio Announces Additional $11.5 Million of FinancingNASDAQ:SNTISenti Biosciences Inc
12/16/20248:00AMGlobeNewswire Inc.Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest TherapeuticsNASDAQ:SNTISenti Biosciences Inc
12/03/20248:00PMGlobeNewswire Inc.Senti Biosciences Announces New Employment Inducement GrantsNASDAQ:SNTISenti Biosciences Inc
12/02/20247:10AMGlobeNewswire Inc.Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity FinancingNASDAQ:SNTISenti Biosciences Inc
12/02/20247:02AMGlobeNewswire Inc.Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AMLNASDAQ:SNTISenti Biosciences Inc
12/02/20247:00AMGlobeNewswire Inc.Senti Bio Appoints Fran Schulz to Board of DirectorsNASDAQ:SNTISenti Biosciences Inc
11/14/20244:05PMGlobeNewswire Inc.Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate HighlightsNASDAQ:SNTISenti Biosciences Inc
09/03/20248:15AMGlobeNewswire Inc.Senti Bio to Participate in Upcoming Investor ConferencesNASDAQ:SNTISenti Biosciences Inc
08/13/20244:05PMGlobeNewswire Inc.Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsNASDAQ:SNTISenti Biosciences Inc
08/05/20248:05AMGlobeNewswire Inc.Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202NASDAQ:SNTISenti Biosciences Inc
07/16/20248:30AMGlobeNewswire Inc.Senti Bio Announces Reverse Stock SplitNASDAQ:SNTISenti Biosciences Inc
07/01/20248:05AMGlobeNewswire Inc.Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell TherapyNASDAQ:SNTISenti Biosciences Inc
05/29/20244:14PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNTISenti Biosciences Inc
05/29/20244:09PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNTISenti Biosciences Inc
05/29/20244:07PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNTISenti Biosciences Inc
05/17/20245:19PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNTISenti Biosciences Inc
05/17/20245:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNTISenti Biosciences Inc
05/13/20248:15AMGlobeNewswire Inc.Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNASDAQ:SNTISenti Biosciences Inc
05/09/20244:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNTISenti Biosciences Inc
05/09/20244:05PMGlobeNewswire Inc.Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsNASDAQ:SNTISenti Biosciences Inc
04/30/20248:05AMGlobeNewswire Inc.Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)NASDAQ:SNTISenti Biosciences Inc
03/21/20244:05PMGlobeNewswire Inc.Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsNASDAQ:SNTISenti Biosciences Inc
01/05/20244:05PMGlobeNewswire Inc.Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramNASDAQ:SNTISenti Biosciences Inc
12/22/20236:30AMGlobeNewswire Inc.Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNASDAQ:SNTISenti Biosciences Inc
11/13/20234:15PMGlobeNewswire Inc.Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNASDAQ:SNTISenti Biosciences Inc
11/06/20234:05PMGlobeNewswire Inc.Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaNASDAQ:SNTISenti Biosciences Inc
10/31/20239:06AMGlobeNewswire Inc.Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:SNTISenti Biosciences Inc
09/27/20239:05AMGlobeNewswire Inc.Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 MeetingNASDAQ:SNTISenti Biosciences Inc
09/26/20234:05PMGlobeNewswire Inc.Senti Bio to Participate in Upcoming ConferencesNASDAQ:SNTISenti Biosciences Inc
09/05/20238:30AMGlobeNewswire Inc.Senti Bio to Participate in Upcoming Investor ConferencesNASDAQ:SNTISenti Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SNTI

Your Recent History

USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
NBRI
North Bay Resources (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
TSLA
Tesla
USOTC
SPZI
Spooz (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
MONI
Moon Equity (PK)
USOTC
RNVA
Rennova Health (CE)
USOTC
RDAR
Raadr (PK)
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
ELTP
Elite Pharmaceuticals (QB)
COIN
XRPUSD
Ripple
USOTC
AABB
Asia Broadband (PK)
NASDAQ
LWLG
Lightwave Logic
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads